Vividion Therapeutics is a biotechnology company focused on developing innovative therapeutics that treat major unmet medical needs using the first platform for proteome-wide small molecule drug discovery. The company's cutting-edge platform is based on seminal work from the labs of Professors Benjamin Cravatt, Phil Baran, and Jin-Quan Yu at The Scripps Research Institute in La Jolla, CA. Vividion previously raised a $45 Million Series A from ARCH Venture Partners, Versant Ventures, and Cardinal Partners. In March 2018, the Company established a multi-year, $101 Million up-front strategic collaboration with Celgene Corporation, aimed at discovering therapeutics against select first-in-class targets, with an initial focus in oncology and inflammation.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/30/19 | $82,000,000 | Series B |
Alexandria Venture Investments Altitude Life Science Ventures ARCH Venture Partners BVF Partners Cardinal Partners Casdin Capital Celgene Corporation Mirae Asset Venture Investment Mubadala Ventures Nextech Invest  Trinitas Capital Versant Ventures | undisclosed |
| 02/24/21 | $135,000,000 | Series C |
Acuta Capital Partners Avoro Capital Advisors BlackRock Boxer Capital BVF Partners Driehaus Capital Management Logos Capital RA Capital Management SoftBank Investment Advisers Surveyor Capital T. Rowe Price Associates Woodline Partners | undisclosed |
